Our purpose is to accelerate the development of cancer medicines and treatments
Talk to our team
We’d like to hear from you
Read the latest news from Ellipses Pharma
ODD granted by FDA
Ellipses EP0031 granted Orphan Drug Designation from the US Food and Drug Administration EP0031/A400, a next generation selective RET inhibitor (SRI), is currently being investigated as a treatment option for patients with RET altered tumours Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug [...]
Ellipses Pharma featured in The Guardian: Innovations In Oncology
Ellipses Pharma features in the Guardian Innovations In Oncology supplement By leveraging a cloud-based platform, our SAG members provide invaluable scientific and clinical insights, validate asset selection, and offer unbiased input during the drug development process using real-world evidence. This collaborative effort ensures better decision-making, faster development, and increased chances of success in bringing potential [...]
“Encouraging” data accelerates clinical programme
Ellipses Pharma announces intent to accelerate clinical programme following ‘encouraging’ data on next generation selective RET inhibitor Chicago June 5, 2023: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical development of the next generation selective RET inhibitor [...]
